Related references
Note: Only part of the references are listed.A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications
George W. Wright et al.
CANCER CELL (2020)
Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial
Andrew Davies et al.
LANCET ONCOLOGY (2019)
Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma
Daisuke Ennishi et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy
Chulin Sha et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
Bjoern Chapuy et al.
NATURE MEDICINE (2018)
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
R. Schmitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma
Anupama Reddy et al.
CELL (2017)
Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue
David W. Scott et al.
BLOOD (2014)
Double-hit B-cell Lymphomas With BCL6 and MYC Translocations Are Aggressive, Frequently Extranodal Lymphomas Distinct From BCL2 Double-hit B-cell Lymphomas
Raju K. Pillai et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2013)
MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma
Heike Horn et al.
BLOOD (2013)
Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing
Ryan D. Morin et al.
BLOOD (2013)
Genetic heterogeneity of diffuse large B-cell lymphoma
Jenny Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
Zijun Y. Xu-Monette et al.
BLOOD (2012)
Integrative Analysis Reveals an Outcome-Associated and Targetable Pattern of p53 and Cell Cycle Deregulation in Diffuse Large B Cell Lymphoma
Stefano Monti et al.
CANCER CELL (2012)
Double-hit BCL2/MYC translocations in a consecutive cohort of patients with large B-cell lymphoma - a single centre's experience
Mette O. Pedersen et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2012)
Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
Tina Marie Green et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
Nathalie A. Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18) (q32;q21): an aggressive disease with heterogeneous histology, germina center B-cell immunophenotype and poor outcome
Shaoying Li et al.
MODERN PATHOLOGY (2012)
Analysis of the coding genome of diffuse large B-cell lymphoma
Laura Pasqualucci et al.
NATURE GENETICS (2011)
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte
Bertrand Coiffier et al.
BLOOD (2010)
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
AA Alizadeh et al.
NATURE (2000)
Share Paper
